Genisphere showcased its 3DNA Dendrimer Signal Amplification technology for Lateral Flow (LF) Point-of-Care (POC) assays at AACC. The technology provides improved sensitivity and enables a broad new array of POC tests. Genisphere’s 3DNA® signal amplifiers will enable the commercialization of new LF assays that otherwise could not be launched due to low sensitivity.
These developments build on previous signal amplification capabilities that have been demonstrated in other systems such as ELISA, protein and DNA arrays, as well as Luminex® assays. Genisphere’s proprietary 3DNA® Dendrimer technology has delivered up to 64-fold improvements in sensitivity over standard, non-dendrimer assays. With this heightened power of detection, the technology can reduce false negatives and significantly increase the accuracy of otherwise-subjective outcome readings.
CLP is the only magazine that focuses exclusively on products and technology for the clinical lab industry. Every month, CLP's editorial provides 45,000 pathologists, lab managers, administrators and technologists with comprehensive coverage of new products and technology.
RSS